H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Nicox SA (0RCQ – Research Report) today and set a price target of €1.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ram Selvaraju has given his Buy rating due to a combination of factors including the advancement of Nicox SA’s NCX 470 into Phase 3 trials in Japan, which has triggered a significant milestone payment. This development not only extends the company’s cash runway to the end of 2025 but also indicates strong progress in their clinical trials. The initiation of these trials by Kowa, Nicox’s partner in Japan, reflects positively on the company’s strategic partnerships and potential for future revenue streams.
Additionally, the anticipated results from the Phase 3 Denali trial in the U.S. and China, expected in the third quarter of 2025, could further bolster Nicox’s position. Positive outcomes from these trials would enable Nicox to submit a new drug application in the U.S. in the first half of 2026. The promising data from the Mont Blanc trial and the exploratory Whistler Phase 3b trial underscore the efficacy of NCX 470, particularly its dual mechanism of action, which enhances its potential as a treatment for ocular hypertension and open-angle glaucoma.
According to TipRanks, Selvaraju is a 4-star analyst with an average return of 9.3% and a 38.99% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Niagen Bioscience, Emergent Biosolutions, and Vanda.